Literatuur

Literatuur

Westcott GF. Serpasil as an adjunct to brief intensive psychotherapy with two psychotic patients. J Nerv Ment Dis. 1956 Jan;123(1):53-6.

Tanck RH. Psychologic changes induced by reserpine therapy on a group of severely disturbed psychotics. J Nerv Ment Dis. 1958 Apr;126(4):353-9.

Nur S, Adams CE. Chlorpromazine versus reserpine for schizophrenia. Cochrane Database Syst Rev. 2016 Apr 28;4:CD012122.

Bennett MR. Monoaminergic synapses and schizophrenia: 45 years of neuroleptics. J Psychopharmacol. 1998;12(3):289-304.

López-Muñoz F, Alamo C, Cuenca E, Shen WW, Clervoy P, Rubio G. History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry. 2005 Jul-Sep;17(3):113-35.

Kushner T. Experience with greater than recommended doses of fluphenazine and triflupromazine. Am J Psychiatry. 1966 Mar;122(9):1061-2.

Marques LO, Lima MS, Soares BG. Trifluoperazine for schizophrenia. Cochrane Database Syst Rev. 2004;2004(1):CD003545.

Hartung B, Sampson S, Leucht S. Perphenazine for schizophrenia. Cochrane Database Syst Rev. 2015 Mar 6;2015(3):CD003443.

Tardy M, Huhn M, Engel RR, Leucht S. Perphenazine versus xlow-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2014 Oct 7;(10):CD009369.

MacCrimmon DJ, Saxena B, Foley P, Grof P. Fluphenazine decanoate and fluphenazine enanthate in the out-patient management of chronic schizophrenia. Neuropsychobiology. 1978;4(6):360-5.

Marjerrison G, Bowman R, Keogh RP. A comparison of chlorprothixene and haloperidol in acute schizophrenia. Can Psychiatr Assoc J. 1971 Dec;16(6):533-6.

Bryan EJ, Purcell MA, Kumar A. Zuclopenthixol dihydrochloride for schizophrenia. Cochrane Database Syst Rev. 2017 Nov 16;11(11):CD005474.

Jayakody K, Gibson RC, Kumar A, Gunadasa S. Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. Cochrane Database Syst Rev. 2012 Apr 18;2012(4):CD000525.

Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, Arndt T, Bäckers L, Rothe P, Cipriani A, Davis J, Salanti G, Leucht S.  Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of 119 adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019 Sep 14;394(10202):939-951.

Coutinho E, Fenton M, Quraishi S. Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses. Cochrane Database Syst Rev. 2000;1999(2):CD001164.

Eberhard G, Hellbom E. Haloperidol decanoate and  flupenthixol decanoate in schizophrenia. A long-term doubleblind cross-over comparison. Acta Psychiatr Scand. 1986 Sep;74(3):255-62.

Gerlach J, Behnke K, Heltberg J, Munk-Anderson E, Nielsen H. Sulpiride and haloperidol in schizophrenia: a double-blind cross-over study of therapeutic effect, side effects and plasma concentrations. Br J Psychiatry. 1985 Sep;147:283-8.

Purgato M, Adams CE. Bromperidol decanoate (depot) for schizophrenia. Cochrane Database Syst Rev. 2012 Nov 14;11(11):CD001719.

Pecknold JC, McClure DJ, Allan T, Wrzesinski L. Comparison of pimozide and chlorpromazine in acute schizophrenia. Can J Psychiatry. 1982 Apr;27(3):208- 12.

Soares BG, Lima MS. Penfluridol for schizophrenia. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD002923.

Lepola U, Koskinen T, Rimón R, Salo H, Gordin A. Sulpiride and perphenazine in schizophrenia. A doubleblind clinical trial. Acta Psychiatr Scand. 1989 Jul;80(1):92-6.

Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016  Nov;209(5):385-392.

Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry. 2007 Mar;18(1):39-60. 

Johnsen E, Kroken RA, Løberg EM, Rettenbacher M, Joa I, Larsen TK, Reitan SK, Walla B, Alisauskiene R, Anda LG, Bartz-Johannessen C, Berle JØ, Bjarke J, Fathian F, Hugdahl K, Kjelby E, Sinkeviciute I, Skrede S, Stabell L, Steen VM, Fleischhacker WW. Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial. Lancet Psychiatry. 2020 Nov;7(11):945-954.

Citrome L, O'Malley SS, McDonnell D, Jiang Y, Simmons AC, Berry MP, Dipetrillo LE. Olanzapine Plus Samidorphan in Subjects with Schizophrenia and Comorbid Alcohol Use Disorder: Rationale and Design for a Phase II, Double-blind, Randomized Study. Innov Clin Neurosci. 2019 May 1;16(5-6):15-21.

Kasper S, Müller-Spahn F. Review of quetiapine and its clinical applications in schizophrenia. Expert Opin Pharmacother. 2000 May;1(4):783-801.

Kasper S, Tauscher J, Heiden A. Quetiapine: efficacy and tolerability in schizophrenia. Eur Neuropsychopharmacol. 2001 Oct;11 Suppl 4:S405-13.

Pajonk FG. Risperidone in acute and long-term therapy of schizophrenia--a clinical profile. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jan;28(1):15-23.

Correll CU. Pharmakotherapie der Schizophrenie [Pharmacotherapy of schizophrenia]. Nervenarzt. 2020 Jan;91(1):34-42.

Ribeiro ELA, de Mendonça Lima T, Vieira MEB, Storpirtis S, Aguiar PM. Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews. Eur J Clin Pharmacol. 2018 Oct;74(10):1215-1233.

Citrome L. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil. Expert Rev Clin Pharmacol. 2016;9(2):169-86.

Mandrioli R, Protti M, Mercolini L. Evaluation of the pharmacokinetics, safety and clinical efficacy of ziprasidone for the treatment of schizophrenia and bipolar disorder. Expert Opin Drug Metab Toxicol. 2015 Jan;11(1):149-74.

Muscatello MR, Bruno A, Micali Bellinghieri P, Pandolfo G, Zoccali RA. Sertindole in schizophrenia: efficacy and safety issues. Expert Opin Pharmacother. 2014 Sep;15(13):1943-53.

Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Janik A, Schotte A, Hough D, Fleischhacker WW. Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study. Int J Neuropsychopharmacol. 2016 Jul 5;19(7):pyw018. 

de Leon J. Personalizing dosing of risperidone, paliperidone and clozapine using therapeutic drug monitoring and pharmacogenetics. Neuropharmacology. 2020 May  15;168:107656.

Bobo WV. Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol. 2013 Jan;6(1):61-91.

Tonin FS, Wiens A, Fernandez-Llimos F, Pontarolo R. Iloperidone in the treatment of schizophrenia: an evidencebased review of its place in therapy. Core Evid. 2016 Dec 14;11:49-61.

Ward K, Citrome L. Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidencebased review and place in therapy. Neuropsychiatr Dis Treat. 2019 Jan 15;15:247-257.

Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments metaanalysis. Lancet. 2013 Sep 14;382(9896):951-62.

Garnock-Jones KP. Cariprazine: A Review in Schizophrenia. CNS Drugs. 2017 Jun;31(6):513-525.

Plosker GL, Deeks ED. Asenapine: A Review in Schizophrenia. CNS Drugs. 2016 Jul;30(7):655-66. 

Bugarski-Kirola D, Arango C, Fava M, Nasrallah H, Liu IY, Abbs B, Stankovic S. Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe. Lancet Psychiatry. 2022 Jan;9(1):46-58.

Greenwood J, Acharya RB, Marcellus V, Rey JA. 138 Lumateperone: A Novel Antipsychotic for Schizophrenia. Ann Pharmacother. 2021 Jan;55(1):98-104.

Adams DH, Zhang L, Millen BA, Kinon BJ, Gomez JC. Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison. Schizophr Res Treatment. 2014;2014:758212.

Bugarski-Kirola D, Blaettler T, Arango C, Fleischhacker WW, Garibaldi G, Wang A, Dixon M, Bressan RA, Nasrallah H, Lawrie S, Napieralski J, Ochi-Lohmann T, Reid C, Marder SR. Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies. Biol Psychiatry. 2017 Jul 1;82(1):8-16.

García-Gutiérrez MS, Navarrete F, Gasparyan A, Austrich-Olivares A, Sala F, Manzanares J. Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression and Psychotic Disorders. Biomolecules. 2020 Nov 19;10(11):1575.

Grauer SM, Pulito VL, Navarra RL, Kelly MP, Kelley C, Graf R, Langen B, Logue S, Brennan J, Jiang L, Charych E, Egerland U, Liu F, Marquis KL, Malamas M, Hage T, Comery TA, Brandon NJ. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther. 2009 Nov;331(2):574-90.

Suzuki K, Kimura H. TAK-063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia. CNS Neurosci Ther. 2018 Jul;24(7):604- 614.

Macek TA, McCue M, Dong X, Hanson E, Goldsmith P, Affinito J, Mahableshwarkar AR. A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia. Schizophr Res. 2019 Feb;204:289-294.

Schlumberger C, Pietraszek M, Gravius A, Klein KU, Greco S, Morè L, Danysz W. Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3)  receptor agonist LY354740 in tests for antipsychotic-like activity. Eur J Pharmacol. 2009 Nov 25;623(1-3):73-83

Schmidt ME, Kent JM, Daly E, Janssens L, Van Osselaer N, Hüsken G, Anghelescu IG, Van Nueten L. A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D2 receptor antagonist in the treatment of acute exacerbation of schizophrenia. Eur Neuropsychopharmacol. 2012 Oct;22(10):721-33.

Vauquelin G, Bostoen S, Vanderheyden P, Seeman P. Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism. Naunyn Schmiedebergs Arch Pharmacol. 2012 Apr;385(4):337-72.

Revel FG, Moreau JL, Pouzet B, Mory R, Bradaia A, Buchy D, Metzler V, Chaboz S, Groebke Zbinden K, Galley G, Norcross RD, Tuerck D, Bruns A, Morairty SR, Kilduff TS, Wallace TL, Risterucci C, Wettstein JG, Hoener MC. A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight. Mol Psychiatry. 2013 May;18(5):543-56.

Correll CU, Koblan KS, Hopkins SC, Li Y, Heather Dworak, Goldman R, Loebel A. Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, openlabel extension study. NPJ Schizophr. 2021 Dec 9;7(1):63.

Daya RP, Bhandari J, Kooner SK, Ho J, Rowley CD, Bock NA, Farncombe T, Mishra RK. The Dopamine Allosteric Agent, PAOPA, Demonstrates Therapeutic Potential in the Phencyclidine NMDA Pre-clinical Rat Model of Schizophrenia. Front Behav Neurosci. 2018 Dec 12;12:302.

Linck VM, Ganzella M, Herrmann AP, Okunji CO, Souza DO, Antonelli MC, Elisabetsky E. Original mechanisms of antipsychotic action by the indole alkaloid alstonine (Picralima nitida). Phytomedicine. 2015 Jan 15;22(1):52-5.

Kishi T, Matsuda Y, Nakamura H, Iwata N. Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials. J Psychiatr Res. 2013 Feb;47(2):149-54.

Cantillon M, Ings R, Bhat L. Initial Clinical Experience of RP5063 Following Single Doses in Normal Healthy Volunteers and Multiple Doses in Patients with Stable Schizophrenia. Clin Transl Sci. 2018 Jul;11(4):387-396.

Rabinowitz J, Badescu S, Palamarchuk P, Filyk V, Voloshchuk A, Rud V, Melnyk E, Skrypnikov A, Davidson M, Saoud J, Luthringer R. Personal and social adjustment effects of roluperidone in patients with schizophrenia and negative symptoms: Results from an exploratory outcome of a randomized placebo-controlled trial. Schizophr Res. 2019 Sep;211:103-104.

Brannan SK, Sawchak S, Miller AC, Lieberman JA, Paul SM, Breier A. Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia. N Engl J Med. 2021 Feb 25;384(8):717-726.

Foster DJ, Bryant ZK, Conn PJ. Targeting muscarinic receptors to treat schizophrenia. Behav Brain Res. 2021 May 7;405:113201.

Robinson DG, Gallego JA, John M, Hanna LA, Zhang JP, Birnbaum ML, Greenberg J, Naraine M, Peters BD, McNamara RK, Malhotra AK, Szeszko PR. A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebocontrolled trial for participants concurrently treated with risperidone Schizophr Res. 2019 Feb;204:295-303.

Litman RE, Su TP, Potter WZ, Hong WW, Pickar D. Idazoxan and response to typical neuroleptics in treatmentresistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. Br J Psychiatry. 1996 May;168(5):571-9.

Chang CH, Lin CH, Liu CY, Chen SJ, Lane HY. Efficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlledtrials. J Psychopharmacol. 2020 May;34(5):495-505.

Kulkarni J, Butler S, Riecher-Rössler A. Estrogens and SERMS as adjunctive treatments for schizophrenia. Front Neuroendocrinol. 2019 Apr;53:100743.

Çakici N, van Beveren NJM, Judge-Hundal G, Koola MM, Sommer IEC. An update on the efficacy of antiinflammatory agents for patients with schizophrenia: a meta-analysis. Psychol Med. 2019 Oct;49(14):2307-2319.

Müller N. COX-2 Inhibitors, Aspirin, and Other Potential Anti-Inflammatory Treatments for Psychiatric Disorders. Front Psychiatry. 2019 May 31;10:375.

Vallée M. Neurosteroids and potential therapeutics: Focus on pregnenolone. J Steroid Biochem Mol Biol. 2016 Jun;160:78-87.

Lintunen J, Lähteenvuo M, Tiihonen J, Tanskanen A, Taipale H. Adenosine modulators and calcium channel blockers as add-on treatment for schizophrenia. NPJ Schizophr. 2021 Jan 21;7(1):1.

Wonodi I, Gopinath HV, Liu J, Adami H, Hong LE, Allen-Emerson R, McMahon RP, Thaker GK. Dipyridamole monotherapy in schizophrenia: pilot of a novel treatment approach by modulation of purinergic signaling. Psychopharmacology (Berl). 2011 Nov;218(2):341-5.

Akhondzadeh S, Mojtahedzadeh V, Mirsepassi GR,Moin M, Amini-Nooshabadi H, Kamalipour A. Diazoxidein the treatment of schizophrenia: novel application of potassium channel openers in the treatment ofschizophrenia. J Clin Pharm Ther. 2002 Dec;27(6):453-9.

Hahn MK, Cohn T, Teo C, Remington G. Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters. Clin Schizophr Relat Psychoses. 2013 Jan;6(4):186-96.

Ooi SL, Green R, Pak SC. N-Acetylcysteine for the Treatment of Psychiatric Disorders: A Review of Current Evidence. Biomed Res Int. 2018 Oct 22;2018:2469486. 

Oya K, Kishi T, Iwata N. Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Hum Psychopharmacol. 2014 Sep;29(5):483-91.

Werner FM, Coveñas R. The Novel Antipsychotic Drug Cariprazine and Cognition Enhancing Drugs: Indications for their Use as the Add-on Therapy in Schizophrenia. Curr Pharm Des. 2021;27(39):4033-4038.

Ordak M, Matras J, Muszynska E, Nasierowski T, Bujalska-Zadrozny M. Magnesium in schizophrenia. Pharmacol Rep. 2017 Oct;69(5):929-934. 

Bloch Y, Applebaum J, Osher Y, Amar S, Azab AN,  Agam G, Belmaker RH, Bersudsky Y. Normobaric hyperoxia treatment of schizophrenia. J Clin Psychopharmacol. 2012 Aug;32(4):525-30.

Zheng W, Zhu XM, Zhang QE, Yang XH, Cai DB, Li L, Li XB, Ng CH, Ungvari GS, Ning YP, Xiang YT. Adjunctive intranasal oxytocin for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials. Schizophr Res. 2019 Apr;206:13-20.

Ritsner MS, Miodownik C, Ratner Y, Shleifer T, Mar M, Pintov L, Lerner V. L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, doubleblind, placebo-controlled, 2-center study. J Clin Psychiatry. 2011 Jan;72(1):34-42.

Cho SE, Na KS, Cho SJ, Kang SG. Low d-serine levels in schizophrenia: A systematic review and metaanalysis. Neurosci Lett. 2016 Nov 10;634:42-51.

Tsai GE, Yang P, Chang YC, Chong MY. D-alanine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 2006 Feb 1;59(3):230-4.

Adage T, Trillat AC, Quattropani A, Perrin D, Cavarec L, Shaw J, Guerassimenko O, Giachetti C, Gréco B, Chumakov I, Halazy S, Roach A, Zaratin P. In vitro and in vivo pharmacological profile of AS057278, a selective d-amino acid oxidase inhibitor with potential antipsychotic properties. Eur Neuropsychopharmacol. 2008 Mar;18(3):200-14.

Seetharam JC, Maiti R, Mishra A, Mishra BR. Efficacy and safety of add-on sodium benzoate, a D-amino acid oxidase inhibitor, in treatment of schizophrenia: A systematic review and meta-analysis. Asian J Psychiatr. 2021 Nov 30;68:102947. 

Serrita J, Ralevski E, Yoon G, Petrakis I. A Pilot Randomized, Placebo-Controlled Trial of Glycine for Treatment of Schizophrenia and Alcohol Dependence. J Dual Diagn. 2019 Jan-Mar;15(1):46-55.

Kishi T, Mukai T, Matsuda Y, Iwata N. Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review. Neuromolecular Med. 2014 Mar;16(1):61-9.

Martinez MC. Famotidine in the management of schizophrenia. Ann Pharmacother. 1999 Jun;33(6):742-7.

Silver H, Aharon N, Hausfater N, Jahjah N. The effect of augmentation with moclobemide on symptoms of schizophrenia. Int Clin Psychopharmacol. 1999 May;14(3):193-5.

Lavreysen H, Ahnaou A, Drinkenburg W, Langlois X, Mackie C, Pype S, Lütjens R, Le Poul E, Trabanco AA, Nuñez JM. Pharmacological and pharmacokinetic properties of JNJ-40411813, a positive allosteric modulator of the mGlu2 receptor. Pharmacol Res Perspect. 2015 Feb;3(1):e00096.

Zhang XY, Zhou DF, Su JM, Zhang PY. The effect of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia. J Clin  Psychopharmacol. 2001 Feb;21(1):85-8.

Miodownik C, Lerner V, Kudkaeva N, Lerner PP, Pashinian A, Bersudsky Y, Eliyahu R, Kreinin A,  Bergman J. Curcumin as Add-On to Antipsychotic Treatment in Patients With Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study. Clin Neuropharmacol. 2019 Jul/Aug;42(4):117-122.

Dixon DA, Fenix LA, Kim DM, Raffa RB. Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: I. Adenosine agonists. Ann Pharmacother. 1999 Apr;33(4):480-8.

Titulaer J, Malmerfelt A, Marcus MM, Svensson TH. Enhancement of the antipsychotic effect of risperidone by sodium nitroprusside in rats. Eur Neuropsychopharmacol. 2019  Nov;29(11):1282-1287.

Sanders LLO, de Souza Menezes CE, Chaves Filho AJM, de Almeida Viana G, Fechine FV, Rodrigues de Queiroz MG, Gonçalvez da Cruz Fonseca S, Mendes Vasconcelos SM, Amaral de Moraes ME, Gama CS, Seybolt S, de Moura Campos E, Macêdo D, Freitas de Lucena D. α-Lipoic Acid as Adjunctive Treatment for Schizophrenia: An Open-Label Trial. J Clin Psychopharmacol. 2017 Dec;37(6):697-701.

Zheng W, Li XH, Yang XH, Cai DB, Ungvari GS, Ng CH, Wang SB, Wang YY, Ning YP, Xiang YT. Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials. Psychol Med. 2018 Jan;48(1):72-81.

Stevović LI, Repišti S, Radojičić T, Sartorius N, Tomori S, Kulenović AD, Popova A, Kuzman MR, Vlachos II, Statovci S, Bandati A, Novotni A, Bajraktarov S, Panfil AL, Maric N, Delić M, Jovanović N. Non-pharmacological interventions for schizophrenia-analysis of treatment guidelines and implementation in 12 Southeast European countries. Schizophrenia (Heidelb). 2022 Mar 1;8(1):10 

Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-76. 

Carlsson A, Carlsson ML. A dopaminergic deficit hypothesis of schizophrenia: the path to discovery. Dialogues Clin Neurosci. 2006;8(1):137-42.

Yang AC, Tsai SJ. New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis. Int J Mol Sci. 2017 Aug 3;18(8):1689.

Stahl SM. Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate. CNS Spectr. 2018 Jun;23(3):187-191.

Nakazawa K, Sapkota K. The origin of NMDA receptor hypofunction in schizophrenia. Pharmacol Ther. 2020 Jan;205:107426. 

Samanta D, Lui F. Anti-NMDA Receptor Encephalitis. 2022 Jul 19. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 

Liang CW, Chen TC. Anti-NMDA receptor encephalitis presenting as fever with undetermined cause. Int J Infect Dis. 2022 Jun 17;122:365-367

Uno Y, Coyle JT. Glutamate hypothesis in schizophrenia. Psychiatry Clin Neurosci. 2019 May;73(5):204-215.

Erhardt S, Schwieler L, Imbeault S, Engberg G. The kynurenine pathway in schizophrenia and bipolar disorder. Neuropharmacology. 2017 Jan;112(Pt B):297-306.

Erhardt S, Schwieler L, Nilsson L, Linderholm K, Engberg G. The kynurenic acid hypothesis of schizophrenia. Physiol Behav. 2007 Sep 10;92(1-2):203-9.

Boros FA, Bohár Z, Vécsei L. Genetic alterations affecting the genes encoding the enzymes of the kynurenine pathway and their association with human diseases. Mutat Res Rev Mutat Res. 2018 Apr- Jun;776:32-45.

Beugelink JK. Schizophrenia. Its pharmacotherapy and backgrounds. Third Updated Scientific Edition. ISBN: 9789464488111. Brave New Books, Amsterdam. 2022; 1-134.